2026 International Congress

October 4-8, 2026. Seoul, Korea.

View by Title View Categories

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

How large must a Parkinson’s disease trial be to detect pharmacogenomic interactions? Power benchmarks derived from the Exenatide PD3 clinical trial

R. Gurney, C. Girges, N. Vijiaratnam, C. Carroll, M. Hu, G. Duncan, M. Silverdale, T. Foltynie (London, United Kingdom)
How Parkinson’s Disease Research Has Shifted from 2016 – 2025 at the MDS Congress: A Topic-Based Analysis

L. Ramin, D. Wolff (Hannover, Germany)
How Remote Coaching Enables Engagement in Physical Activity for People with Parkinson’s Disease in Qatar: A Qualitative Study of Participant and Therapist Perspectives

M. Elamin, Y. Abdulmaguid, R. Abdelsamad, T. Ahmad, M. Shoukry, L. Mohammad, M. Rawash, M. Abunaib, S. Koyili, I. Eltazi, L. Morris, T. Hartley, M. Latrous, M. Almusallam, L. Quinn, H. Khalil (Doha, Qatar)
Hula as an Integrative Movement-Based Therapy: Baseline Cohort Characteristics

R. Shuman, E. Krening, K. Tolentino, M. Yee, K. Thai, M. Faouzi, M. Bruno (Honolulu, USA)
Human Snca Knock-In Mouse as a Model for Synucleinopathy Research

E. Cinar, J. Ma, Y. Liang, K. Luk (Philadelphia, USA)
Huntington’s Disease Genetic Testing Practices in the Lower North Island of New Zealand

D. Llewelyn, D. Bourke (Wellington, New Zealand)
Hybrid deep brain stimulation conversion using the S8 adaptor in Parkinson’s disease

MG. Choi, SJ. Chung, SY. Jo, GY. Lee (Seoul, Republic of Korea)
Hyperkinetic Movement Disorder as the First Manifestation of Gaucher Disease Type 3

B. Kocer, E. Ercan (Ankara, Turkey)
Iatrogenic akathisia aggravating depressive and psychotic symptoms: a case report

A. Katok, D. Khasanova (Kazan, Russian Federation)
Icariin, a Flavonoid from Epimedium, Confers Dopaminergic Neuroprotection and Neuromodulation in MPTP-Induced Parkinsonian Rats

A. Singh (Allahabad, India)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z